Linked Life Data

19668023

Source:http://linkedlifedata.com/resource/pubmed/id/19668023

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-9-9
pubmed:abstractText
Complaints of loss of memory and lack of concentration have been reported by long-term survivors of breast cancer. This mild cognitive impairment (MCI), also called "chemobrain" or "chemofog," has been the subject of a number of studies in the last few years. This cognitive impairment, although usually mild, must be studied to define possible risk factors for its development, and for future research into a preventive or therapeutic treatment approach. Long-term survivors of breast cancer must be followed to detect possible treatment sequelae as soon as possible. Since the number of these long-term survivors has increased in the last years, in part because of more active adjuvant treatments, our knowledge about the long-term side effects of these therapies has also grown.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1541-8243
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
929-34
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Adjuvant chemotherapy for breast cancer and cognitive impairment.
pubmed:affiliation
Medical Oncology Department, Hospital La Paz, Madrid, Spain. alvaro_pinto_marin@hotmail.com
pubmed:publicationType
Journal Article, Review